Cancer screening in inflammatory myopathies. Clinical subtypes and specific auto-autoantibodies are the main predictors. Screening should be performed every year in the first 3-5 years after the diagnosis of myopathy in high risk profiles. #EULAR2019 #Myositis https://t.co/iCHYaUHYaA